Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Equity Dilution PHVS has strong liquidity and minimal debt, but no revenue, substantial losses, negative cash flow, equity-driven dilution, and continued reliance on financing weaken the investment case.
Price Behavior
Key Price Behavior Insights: ⢠Support Holds ⢠Resistance Test ⢠Sharp Reversals Support Level: $35.14â$35.32; deeper support $34.04â$34.45 Resistance Level: $36.39â$36.46 Over the last month, PHVS gained 6% and remains bullish above $35 support, but near-overbought momentum, resistance at $36.39â$36.46, and sharp reversals make a breakout or pullback likely.
Sentiment & News
Key News Insights: ⢠FDA review accepted ⢠Phase 3 catalysts ⢠Insider share sale Pharvaris advanced deucrictibant with FDA acceptance and an April 2027 decision date, while upcoming Phase 3 data could drive catalysts despite insider selling and uncertain analyst targets.
AI Summary
PHVS now offers a credible path to commercialization following FDA acceptance, but its premium valuation makes CHAPTER-3 success and eventual approval criticalâinvestors should treat it as a high-upside, binary biotech and monitor clinical results, cash burn, and dilution closely.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |